OncoBriefs - Oncology Research News

May 04, 2026

The Liver Sequel Nobody Asked For

The Liver Sequel Nobody Asked For

If this study were a prestige TV drama, the surgeons would spend an entire season pulling off a heroic finale, only for the villain to sneak back into the same apartment building through the side door. That, in plain English, is the problem with colorectal cancer that has spread to the liver: even...

May 03, 2026

Colorectal Cancer’s New Passport Stamp Problem

Colorectal Cancer’s New Passport Stamp Problem

Colorectal cancer used to behave like a stew you forgot on the back burner - mostly a problem that showed up later, after years of simmering. Now it is barging into the kitchen early, showing up in younger adults and in more parts of the world, which is less "grandma's slow recipe" and more "who...

May 03, 2026

Duvelisib Just Went Up for Auction, and Relapsed PTCL Finally Heard a Bid Worth Noticing

Duvelisib Just Went Up for Auction, and Relapsed PTCL Finally Heard a Bid Worth Noticing

Going once, going twice, sold - not to miracle hype, but to something much rarer in relapsed peripheral T-cell lymphoma: a result that actually makes oncologists put down their coffee and squint at the screen again.

May 03, 2026

The Tiny Trash Can With a Side Hustle

The Tiny Trash Can With a Side Hustle

If you learned about lysosomes in school, you probably got the discount version: they're the cell's garbage disposals. Which is true in the same way calling a hospital "a building with chairs" is technically true but emotionally unsatisfying.

May 03, 2026

Tim-3, Ferroptosis, and the Liver’s Very Bad Neighborhood

Tim-3, Ferroptosis, and the Liver’s Very Bad Neighborhood

Dispatch from inside the liver: the streets are slick with fat, oxidative stress is drifting through the air like tear gas, and the dendritic cells - the immune system's field reporters - are going down before they can get the message to the CD8 T-cell cavalry.

May 03, 2026

Two patients, one treatment plan, zero room for autopilot

Two patients, one treatment plan, zero room for autopilot

Blood cancers during pregnancy are rare, but rare does not mean simple. It means every decision feels like it was designed by a committee of chaos goblins. The doctor is not just treating a cancer. They are balancing the health of the pregnant patient, the timing of the pregnancy, the type of...

May 03, 2026

Viruses Are Being Asked to Fix the Worst Party in Cancer

Viruses Are Being Asked to Fix the Worst Party in Cancer

The ending first: tumors can sometimes be shoved from "immune dead zone" to "active crime scene" with engineered viruses and cytokine gene therapy. The rewind is where it gets weird, because yes, this means doctors are using carefully modified viruses to make cancer more visible to your immune...

May 03, 2026

When Blood Starts Gossiping About Your Lymphoma

When Blood Starts Gossiping About Your Lymphoma

What is identity, really, if not a pattern that keeps reappearing even when the furniture changes? Cancer, annoyingly enough, seems to agree, because a large B-cell lymphoma can leave behind tiny molecular fingerprints in the bloodstream long before a scan fully settles the argument.

May 03, 2026

When Brain Housekeepers Start Moonlighting for the Tumor

When Brain Housekeepers Start Moonlighting for the Tumor

Help wanted: Star-shaped brain cell seeks flexible role in neighborhood management. Duties include feeding neurons, keeping the blood-brain barrier tidy, and, under unfortunate management, helping a tumor tell the immune system to take a very long coffee break.

May 02, 2026

Abexinostat: The Pill That Tells Cancer to Read Its Own Instruction Manual Again

Abexinostat: The Pill That Tells Cancer to Read Its Own Instruction Manual Again

Things follicular lymphoma cells are good at: dodging the immune system, staging comebacks after treatment, and - apparently - ignoring the genetic instruction manual that's supposed to keep them from going rogue. A new drug called abexinostat is here to fix that last one, and the results are...

May 02, 2026

Remission Is Not the End Credits

Remission Is Not the End Credits

Hodgkin lymphoma has one of the better reputations in cancer medicine, which sounds nice until you realize "better reputation" can hide a lot of mess. Cure rates are high. Treatments keep improving. Doctors have gotten much better at knocking the disease down. But this new Danish study asks the...

May 02, 2026

The Tumor Has a Vibe, Unfortunately

The Tumor Has a Vibe, Unfortunately

A quick translation. DNA methylation does not rewrite the genetic code. It acts more like editorial markup on top of it. Same script, different stage directions. In cancer, those stage directions can get weird fast.

May 02, 2026

The Verdict on the Androgen Receptor: Guilty, but the Defense Just Found a Loophole

The Verdict on the Androgen Receptor: Guilty, but the Defense Just Found a Loophole

The prosecution rested years ago. The androgen receptor (AR) was found guilty of driving prostate cancer - case closed, gavel down, everybody go home. Doctors threw the book at it with drugs like enzalutamide that clamp down on AR's ligand-binding domain like handcuffs on a suspect. But here's...

May 02, 2026

The scouting report on tired T cells

The scouting report on tired T cells

Your CD8 T cells are supposed to be the closer, the pass rush, the late-game assassin - pick your sport. They find infected or malignant cells, hit them hard, and keep the scoreboard moving in your favor. But when a fight drags on, those same cells can slide into T cell exhaustion, a state where...

May 02, 2026

When You Pull Weeds and Flowers Together, Everything Looks Like Dirt

When You Pull Weeds and Flowers Together, Everything Looks Like Dirt

A gardener who rips out every plant in the bed - roses and crabgrass alike - then concludes "nothing here was worth growing" hasn't really proven anything about roses. That, in a nutshell, is what three prominent Alzheimer's researchers just argued happened to the latest big-ticket review of...

May 02, 2026

When the Scan Lit Up the Room: JYP0322 Takes a Swing at ROS1's Nastiest Tricks

When the Scan Lit Up the Room: JYP0322 Takes a Swing at ROS1's Nastiest Tricks

The moment the first scan showed that a heavily pretreated ROS1-positive lung cancer had actually shrunk - and not just in the chest, but in the place doctors dread most, the brain - the researchers likely did what scientists do when they're internally screaming: they opened a spreadsheet and tried...

May 02, 2026

Your Body's Fat Is Helping Cancer Sneak Into Your Lungs - And a Diabetes Drug Might Stop It

Your Body's Fat Is Helping Cancer Sneak Into Your Lungs - And a Diabetes Drug Might Stop It

The smell of palmitic acid in a centrifuge tube is unremarkable - a faint, waxy nothing. It's the kind of molecule you'd walk right past in a lab without a second thought. But researchers at Nanjing University just caught this boring little fatty acid red-handed, running one of the most devious...

May 01, 2026

CDK Inhibitors: The Brakes, the Breakouts, and the Backup Plans

CDK Inhibitors: The Brakes, the Breakouts, and the Backup Plans

The problem with breast cancer's growth engine is that it does not just hit the gas - it studies the brake system, hires a locksmith, and comes back with a grudge. That is the world cyclin-dependent kinase, or CDK, inhibitors enter: a fight over whether cancer cells get to keep dividing like they...

May 01, 2026

MARCO Promotes Cholangiocarcinogenesis

MARCO Promotes Cholangiocarcinogenesis

Introducing MARCO: the immune receptor that helps tumors hide from your body's defenses - and the antibody that might shut it down.